Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

Dayton Children's Hospital

Status: Withdrawn

Conditions: Cystic Fibrosis

Study type: Observational

Funder types: Other

Identifiers

NCT02048163

DCH 2013-034

Details and patient eligibility

About

The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.

Full description

1. To assess the number of episodes of emesis following both short and prolonged intermittent infusion of meropenem.
2. To assess the number of episodes of emesis corresponding to the peak serum concentration of meropenem.
3. To assess the number of episodes of emesis corresponding to the area under the meropenem serum concentration time curve.
4. To assess reported nausea, measured through administered dosages of anti-nausea medication, following both short and prolonged intermittent infusion of meropenem.
5. To assess reported nausea, measured through administered doses of anti-nausea medication, corresponding to peak concentrations of meropenem.
6. To assess reported nausea, measured through administered dosages of anti-nausea medication, corresponding to the area under the serum concentration time curve
7. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity of nausea in pediatric patients, following both short and prolonged intermittent infusion of meropenem.
8. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity corresponding to the peak serum concentrations of meropenem.
9. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity corresponding to the area under the meropenem serum concentration time curve.

Sex: All

Ages: 7 to 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Be an admitted patient at Dayton Children's Hospital.

2. Between 7 and 21 years of age.

3. Have a documented CF diagnosis with one or more of the following clinical features:

   1. Sweat chloride > 60 mEq/liter as determined by quantitative pilocarpine iontophoresis test (QPIT).
   2. Two mutations (well characterized) in the cystic fibrosis transmembrane conductive regulator (CTFR) gene.
   3. Abnormal nasal potential difference.

4. Based on Hankinson/NHanes III criteria, are able to elicit an FEV1 > 25% but with < 95% predicted value when admitted.

5. Sputum or throat swab specimen positive for P. aeruginosa and have a history of at least one additional sputum culture positive for P. aeruginosa within the last 12 months.

6. Are able to perform an acceptable spirometry session (defined as 3 acceptable or usable efforts per ATS/ERS criteria upon admission).

7. Have not smoked tobacco within 28 days prior to Visit 1 and agree not to smoke for the duration of the study.

8. Are able to and have given written informed consent (if they are adults) or assent in combination with consent of their legal representative(s) (if they are minors) in a manner approved by the Institutional Review Board.

9. Patient is experiencing symptoms of CF exacerbation of CF: with any 4 of the following 12 signs or symptoms:

   • Change in sputum;
   • New or increased hemoptysis;
   • Increased cough;
   • Increased dyspnea;
   • Malaise, fatigue or lethargy;
   • Temperature above 38°C;
   • Anorexia or weight loss;
   • Sinus pain or tenderness;
   • Change in sinus discharge;
   • Change in physical examination of the chest;
   • Decrease in pulmonary function by 10 percent or more from a previously recorded value;
   • Radiographic changes indicative of pulmonary infection.

Exclusion criteria

1. History of hypersensitivity or intolerance to meropenem.
2. History of hypersensitivity or intolerance to granisetron.
3. Are pregnant, breastfeeding, or unwilling to practice a highly effective method of birth control or abstinence during participation in the study.

Trial design

0 participants in 2 patient groups

Short infusion meropenem

Description:

Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.

Prolonged infusion meropenem

Description:

Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.